let's really scrutinise msb, page-8

jeroenn1 I have answered this quest before, and I will so again , but I would like to address your subject heading, Do you not think TEVA , LONZA, M@G and major holders have not scrutinised MSB. lets look at M@G. If you dont know them look at thier corparate website they have $200 bill. under management and have purchased over 30 mill MSB shares over the last 14 months and continue to do so .. Thier average price is around $6.50 thats about $180.mill and you say MSB is pushing elephants up a hose, try telling that to the worlds best outfits .. Some people jump on here and critise without knowledge of the company .. In regards to the bone marrow application , MSB has put it in the warming oven and the obivious reason is CHF, D2, Disc repair , RA are blockbusters compared to BM ,MSB are going to funnell thier and big Pharmas money into the market value applications ie. Rhematoid Arthritis has a glogal tag of $10 bill some of the above mentioned have a higher figure ..jeroenn1 also have a look at TEVA and LONZA Our CEO only deals with the best, and as late this morning I posted MSB as selecting a company MEDIDATA Nasdaq(MDSO)to enhance all of MSB,s clinical trials ..(btw MDSO) is up around 137% @ around $ 40 over the last 12 months ..MSB does due dillegence and only picks winners ... Cheers Vin